Medtronic plc (MDT) operating KPIs

MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026Score 19/303% below fair value

$96.54−0.57 (-0.59%)

Close on Oct 30, 2026Market cap $123.49BP/E 23.7Yield 2.94%

Medtronic diabetes Portfolio (Consolidated Segment) — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M) ($M)

Legacy geographic split reported continuously from FY2016Q1 through FY2024Q4; replaced by unified International division tables starting FY2025Q1.

Quarterly Annual

Latest, FY2024

1,284

Period ended Apr 30, 2024

Change on a year earlier

+16.1%

1,106 in FY2023

History

10 years

Since FY2015

Sources

Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Diabetes Portfolio (Consolidated Segment) — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M) ($M)	Year on year	Source
FY2024	Apr 30, 2024	1,284	+16.1%	Medtronic SEC 8K_EARNINGS — FY2024Q4 (filed 2024-05-23) ↗
FY2023	Apr 30, 2023	1,106	+1.9%	Medtronic SEC 8K_EARNINGS — FY2024Q4 (filed 2024-05-23) ↗
FY2022	Apr 30, 2022	1,085	+6.5%	Medtronic SEC 8K_EARNINGS — FY2023Q4 (filed 2023-05-25) ↗
FY2021	Apr 30, 2021	1,019	+8.4%	Medtronic SEC 8K_EARNINGS — FY2022Q4 (filed 2022-05-26) ↗
FY2020	Apr 30, 2020	940	+9.9%	Medtronic SEC 8K_EARNINGS — FY2021Q4 (filed 2021-05-27) ↗
FY2019	Apr 30, 2019	855	0.0%	Medtronic SEC 8K_EARNINGS — FY2020Q4 (filed 2020-05-21) ↗
FY2018	Apr 30, 2018	855	+36.8%	Medtronic SEC 8K_EARNINGS — FY2019Q4 (filed 2019-05-23) ↗
FY2017	Apr 30, 2017	625	0.0%	Medtronic SEC 8K_EARNINGS — FY2018Q4 (filed 2018-05-24) ↗
FY2016	Apr 30, 2016	625	+7.0%	Medtronic SEC 8K_EARNINGS — FY2017Q4 (filed 2017-05-25) ↗
FY2015	Apr 30, 2015	584	–	Medtronic SEC 8K_EARNINGS — FY2016Q4 (filed 2016-05-31) ↗

Breakdown

What makes up diabetes portfolio (consolidated segment) — non-u.s. developed markets revenue (legacy through fy2024q4, $m)

Diabetes Portfolio (Consolidated Segment) — Non-U.S. Developed Organic Growth (Legacy through FY2024Q4, %)12.7% · FY2024

Cite this data

StockData. (2026). Medtronic Diabetes Portfolio (Consolidated Segment) — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M) ($M), annual FY2015–FY2024 [Data set]. Compiled from Medtronic SEC filings and investor materials. https://stockdatahq.com/stocks/mdt/kpis/diab-seg-dev-leg-rev

See every metric in the Medtronic KPI table. Data updated Oct 31, 2026.